C-Terminal Amidation: Chemistry, Function and Lab Handling
October 21, 2026 · STEPHAN ZOHAR
C-terminal amidation replaces the free carboxyl group (-COOH) at the end of a peptide with a carboxamide (-CONH2). The change removes a negative charge at neutral pH, usually raises receptor affinity, and protects the peptide from some exopeptidases. It is also easy to get wrong in the lab: the wrong terminus changes solubility, assay results and the mass you should see on a certificate of analysis. This guide covers the chemistry, the biology, the synthesis routes and the checks that matter when you order or use an amidated peptide.
TL;DR
- Amidation converts the C-terminal -COOH into -CONH2, which neutralizes the terminal negative charge and caps the chain end.
- Roughly half of all neuropeptide hormones are amidated in vivo by PAM, the only known mammalian enzyme that performs the reaction.
- In research peptides, the amide is usually installed during solid-phase synthesis on an amide-forming resin, not enzymatically.
- Confirm the terminus by intact mass: an amide and a free acid differ by about 1 Da, so the COA needs real mass data, not only an HPLC purity figure.
- Amidation can lower solubility, so plan your buffer and reconstitution before the vial arrives.
Table of Contents
- What the C-terminus is and why it matters
- What amidation changes in a peptide
- How cells make amidated peptides
- How amidated research peptides are made
- Verifying the amide: what to look for on a COA
- Practical handling of amidated peptides
- Our perspective on amidation and quality
- Where to source research peptides
- FAQ
- Sources
What the C-terminus is and why it matters
Every polypeptide has two chemically different ends. The N-terminus carries a free α-amino group, and the C-terminus typically ends in a free α-carboxyl group. Near physiological pH the amino end is protonated and positive, while the carboxyl end is deprotonated and negative.
That negative charge is not trivial. It affects:
- the net charge of short peptides, where one charge is a large fraction of the total;
- salt bridges and hydrogen bonds with a receptor or a binding pocket;
- recognition by carboxypeptidases, which act on free C-termini;
- solubility and retention on reverse-phase columns.
With amidation, the terminal group becomes CONH2. It no longer ionizes, so the C-terminus is effectively capped and the peptide looks more like the interior of a longer protein chain, where the carboxyl group is already tied up in a peptide bond.
What amidation changes in a peptide
Charge and solubility
Because the terminal carboxylate disappears, an amidated peptide carries one fewer negative charge than its free-acid twin at neutral pH. For a short, hydrophobic sequence this can reduce solubility. A peptide supplier’s technical note on end modifications makes the same point: N-terminal acetylation and C-terminal amidation reduce overall charge, so solubility might decrease. If you work with a sequence that is already near its isoelectric point at your assay pH, the amide may push it toward aggregation. Test reconstitution on a small aliquot first.
Receptor binding
For many peptide hormones the amide is part of the pharmacophore. A classic structure-activity review of 45 bioactive peptides concluded that the C-terminal amide is required for the full biological activity of most amidated peptide hormones. Reviews of the amidating enzyme describe affinity losses for non-amidated forms that can be on the order of 100-fold, depending on the peptide and receptor. Treat that figure as a ceiling seen in specific cases, not a rule for every sequence.
Stability
A free C-terminus is a handle for carboxypeptidases. Capping it with an amide protects against that degradation, which is one reason amidation is used in the design of analogs with longer half-lives. In a buffer-only assay this matters less. In serum, plasma, cell lysate or tissue homogenate it can change what you measure over time.
How cells make amidated peptides
In mammals, amidation is a post-translational step. The precursor peptide is synthesized with an extra glycine at its C-terminus. The bifunctional enzyme peptidylglycine α-amidating monooxygenase (PAM) then converts it in two reactions, as described in a review of PAM biology:
- The PHM domain hydroxylates the α-carbon of the terminal glycine. This step needs copper, molecular oxygen and ascorbate.
- The PAL domain, a zinc-dependent lyase, cleaves the Cα-N bond. This releases the amidated peptide and glyoxylate.
PAM is the only known mammalian enzyme that does this conversion, and the modification is found at the C-terminus of about 50% of neuropeptide hormones. PAM matters beyond the bench chemistry: mice lacking it do not survive past mid-gestation, and reduced PAM activity has been linked to psychiatric and metabolic phenotypes, which is why it is studied as a therapeutic target and biomarker.
A pitfall for in vitro enzymatic work
If you attempt enzymatic amidation of a glycine-extended substrate in a dish, remember that PAM is not a single-substrate enzyme. It needs copper, oxygen and ascorbate, and the cofactors must be present in the buffer at workable concentrations. Missing ascorbate or chelators such as EDTA carried over from another step are common reasons for low conversion. The enzymatic route has been used for glycine-extended peptides, but most labs buy the finished amide instead.
How amidated research peptides are made
Solid-phase synthesis on an amide-forming resin
For routine research peptides, the terminus is decided at the start of synthesis by the resin. Fmoc chemistry on a Rink amide-type resin releases the peptide as a C-terminal amide when the final trifluoroacetic acid (TFA) cleavage step is done. A Wang-type resin gives the free acid. The sequence you order and the resin the manufacturer chooses must agree, which is why the terminus belongs in the order specification and not only in a note.
There are side reactions to know about. Decomposition of the Rink amide linker during TFA cleavage can alkylate the C-terminal amide, and the same study reports that adding 1,3-dimethoxybenzene to the cleavage mixture prevents almost all of it. These by-products can look like small impurity peaks and have masses higher than the target. For more on the reagents involved, see our guide to peptide synthesis reagents.
Post-synthetic and emerging routes
Producing amides at preparative scale is harder than it looks for recombinant or semi-synthetic peptides, because a recombinant expression system gives you a free acid. A 2024 paper in Nature Communications describes a photochemical, decarboxylative approach that converts C-terminal acids to amides after the peptide is made, aimed at the fact that preparative methods for amidated pharmaceuticals are limited in both lab and manufacturing settings. A broader review covers recent advances in C-terminally modified peptides and notes that terminal modifications influence activity, stability, hydrophobicity and membrane permeability.
Verifying the amide: what to look for on a COA
An HPLC purity of 98% tells you that one peak dominates. It does not tell you that the peak has the right terminus. A free acid and an amide of the same sequence differ by only about 0.98 Da (OH replaced by NH2), and they can elute close together. Identity needs mass spectrometry.
Use this checklist when you review a certificate:
| Check | What you want to see |
|---|---|
| Sequence and termini listed | C-terminus written as -NH2 (amide) or -OH (acid), matching your order |
| Theoretical monoisotopic or average mass | Calculated for the amide form, not the acid |
| Observed mass | Within the instrument’s stated tolerance of the theoretical value |
| Chromatogram | Trace and integration method attached, with the detection wavelength |
| Lot number | Matches the vial you received |
A few practical notes:
- Do the arithmetic yourself. Amidation of an otherwise identical sequence lowers the neutral mass by about 0.984 Da relative to the acid. On a low-resolution instrument that is easy to miss, so ask for high-resolution data when the terminus is the question.
- Look for the precursor. If you work with glycine-extended precursors and their amidated products, the mass shift between them is -58.0055 Da (C2H2O2). The same source notes the two forms elute at almost identical reverse-phase retention times in biological matrices, so retention time alone cannot separate them.
- Check for +alkylation peaks. Small peaks above the target mass can come from the cleavage side reaction described above.
Our articles on reading a peptide COA, HPLC versus mass spectrometry for peptide QC and what “research grade” should mean on a COA go deeper on each of these checks, and the primer on peptide purity explains why purity and identity are separate questions.
Practical handling of amidated peptides
Reconstitution. Start with a small aliquot. If the amidated peptide is slow to dissolve in water, a small amount of dilute acetic acid for basic sequences is a common approach; see our notes on acetic acid in peptide protocols. Avoid vigorous vortexing that can foam and denature longer sequences.
Concentration. Do not rely on the weighed mass alone. Lyophilized peptides contain counterions and water, so the peptide content is lower than the vial weight. Our methods guide to measuring peptide concentration covers UV and amino acid analysis approaches.
Design stage. If you are choosing between an amide and an acid before ordering, think about the question first. Is the peptide a mimic of a natural amidated hormone? Will it be tested in serum? Is it a fragment that will be coupled to a carrier through its C-terminus, where a free carboxyl is needed? Our piece on peptide sequence design basics walks through these decisions so you avoid reordering.
Storage. Keep lyophilized material cold and dry, and avoid repeated freeze-thaw of solutions. The amide bond itself is stable, but the rest of the sequence (methionine, cysteine, tryptophan) may not be.
Our perspective on amidation and quality
From our side of the bench, the terminus is one of the most common specification errors in peptide orders. A researcher requests a hormone analog, the sequence is entered without a terminal note, and the lot arrives as a free acid. The HPLC trace looks clean and the purity number is high, yet the compound behaves differently in the assay.
That is why we hold to a simple rule: purity and identity are reported separately, and both are tied to a lot. Every lot we sell is independently tested by HPLC and mass spectrometry, with a third-party certificate of analysis published per lot. When a peptide has a modified terminus, we recommend you check the observed mass against the theoretical mass of the intended form, not the generic sequence mass. If the numbers differ by about 1 Da, ask questions before you start an experiment.
All of our products are for laboratory research only. They are not approved for human or veterinary use, and we supply verified researchers.
— Stephan
Where to source research peptides
If you are looking for lyophilized research peptides with lot-specific documentation, our catalog is organized by research area, including Healing & Recovery, Growth Hormone and GLP & Metabolic peptides, along with lab supplies such as bacteriostatic water. Each product ships with a certificate of analysis, and US shipping terms are listed on the shipping and returns page. For a wider look at what to demand from a supplier, see our US supplier guide to high purity peptides.
FAQ
What does C-terminal amidation do to a peptide?
It replaces the terminal carboxyl group with an amide, which removes the negative charge at neutral pH. In many bioactive peptides this raises receptor affinity and reduces degradation by carboxypeptidases. It can also lower solubility because the peptide carries less net charge.
Is the C-terminus positive or negative?
A free C-terminus ends in a carboxyl group, which is deprotonated and negative near physiological pH. The N-terminus is usually protonated and positive. Amidating the C-terminus removes the negative charge, leaving the N-terminal amine as the only terminal charge.
How can I tell whether a peptide is amidated?
Compare the observed mass on the COA with the theoretical mass of the amide form. The acid and amide differ by roughly 0.98 Da, so high-resolution mass spectrometry is the reliable check. HPLC alone cannot confirm the terminus, because retention times can be close.
Do I need an amide or a free acid for my experiment?
Choose the amide if you are mimicking a natural amidated hormone or testing in biological fluids where carboxypeptidases are active. Choose the free acid if the natural peptide has one, or if you plan to couple through the C-terminal carboxyl. When in doubt, check the reference sequence for the peptide you are studying.
Sources
- A Mass Spectrometry-Based Method to Screen for α-Amidated Peptides
- Ciliary and cytoskeletal functions of an ancient monooxygenase essential for bioactive amidated peptide synthesis
- The peptide bond and primary structure, Foundations of protein structure (EMBL-EBI)
- C-terminal amidated peptides: production by the in vitro enzymatic amidation of glycine-extended peptides and the importance of the amide to bioactivity
- PAM: diverse roles in neuroendocrine cells, cardiomyocytes, and green algae
- Peptidylglycine α-amidating monooxygenase as a therapeutic target or biomarker
- C-terminal N-alkylated peptide amides resulting from the linker decomposition of the Rink amide resin
- Photochemically-enabled, post-translational production of C-terminal amides
- Recent Advances in the Synthesis of C-Terminally Modified Peptides
Recommended
This article summarizes published research for informational purposes. Products sold by Neo Lab Peptides are for laboratory research use only and are not intended for human or animal use.